Integer Holdings Corporation Common Stock (ITGR)
122.73
0.00 (0.00%)
Integer Holdings Corp is a leading provider of advanced medical devices and components, specializing in the design and manufacture of innovative solutions for the healthcare industry
The company focuses on developing products that support critical therapeutic and diagnostic applications, catering to a diverse range of medical markets including cardiovascular, orthopedics, and neuromodulation. Integer's expertise encompasses a variety of technologies, enabling it to deliver high-quality, reliable medical products that enhance patient outcomes and drive advancements in healthcare. Through strategic partnerships and a commitment to innovation, Integer Holdings Corp plays a vital role in improving lives and expanding the possibilities of medical technology.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at STAAR Surgical (NASDAQSTAA) and the best and worst performers in the medical devices & supplies - specialty industry.
Via StockStory · February 28, 2025

Via Benzinga · February 21, 2025

Medical technology company Integer Holdings (NYSEITGR) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 11.1% year on year to $449.5 million. The company’s full-year revenue guidance of $1.86 billion at the midpoint came in 1.1% above analysts’ estimates. Its non-GAAP profit of $1.43 per share was 2% below analysts’ consensus estimates.
Via StockStory · February 20, 2025

Medical technology company Integer Holdings (NYSEITGR)
will be announcing earnings results tomorrow before market hours. Here’s what you need to know.
Via StockStory · February 19, 2025

Via Benzinga · January 24, 2025

Via Benzinga · October 21, 2024

ITGR stock results show that Integer Holdings beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
Via InvestorPlace · July 25, 2024

Esther Takeuchi tackled a tough first project after joining private company Greatbatch.
Via Investor's Business Daily · July 25, 2024

Via Benzinga · July 16, 2024

Truist Securities initiates coverage on Integer. With a Buy rating and a $137 target, Integer is poised for significant gains driven by organic growth and strategic acquisitions.
Via Benzinga · May 15, 2024

Via Benzinga · May 15, 2024

Via Benzinga · April 26, 2024

ITGR stock results show that Integer Holdings beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via InvestorPlace · April 25, 2024

BofA Securities' upgrades Integer, highlighting the growth potential of pulsed field ablation (PFA) in atrial fibrillation treatment. With projections of PFA sales skyrocketing from $100-200 million in 2023 to over $2 billion in 2025, Integer emerges as a key supplier for major PFA device manufacturers
Via Benzinga · April 15, 2024

Among its other key ratings Dexcom has a near-best 98 Earnings Per Share Rating out of 99, reflecting strong profit growth this past year.
Via Investor's Business Daily · March 26, 2024

The Relative Strength (RS) Rating for Edwards Lifesciences stock jumped into a new percentile Tuesday, with a rise from 78 to 81.
Via Investor's Business Daily · March 19, 2024

On Monday, Tandem Diabetes Care stock received an upgrade to its Relative Strength (RS) Rating, from 68 to 78.
Via Investor's Business Daily · March 11, 2024

Companies Reporting Before The Bell • Cognex (NASDAQCGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million.
Via Benzinga · February 15, 2024

U.S. stocks traded lower, with the Nasdaq Composite falling more than 90 points on Thursday. Here are some big stocks bucking the trend and recording gains in today’s session.
Via Benzinga · October 26, 2023